Garenoxacin

Garenoxacin

Clinical data
Routes of administration	Oral
ATC code	J01MA19 (WHO)
Identifiers
IUPAC name 1-Cyclopropyl-8-(difluoromethoxy)-7-[(1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
CAS Number	194804-75-6 N
PubChem CID	124093
ChemSpider	110579 N
UNII	V72H9867WB
KEGG	D04031 Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C23H20F2N2O4
Molar mass	426.412 g/mol
3D model (JSmol)	Interactive image
SMILES FC(F)Oc1c(ccc2c1N(/C=C(\C2=O)C(=O)O)C3CC3)c4ccc5c(c4)CN[C@@H]5C
InChI InChI=1S/C23H20F2N2O4/c1-11-15-5-2-12(8-13(15)9-26-11)16-6-7-17-19(21(16)31-23(24)25)27(14-3-4-14)10-18(20(17)28)22(29)30/h2,5-8,10-11,14,23,26H,3-4,9H2,1H3,(H,29,30)/t11-/m1/s1 N Key:NJDRXTDGYFKORP-LLVKDONJSA-N N
NY (what is this?)  (verify)

WikiDoc Resources for Garenoxacin
Articles
Most recent articles on Garenoxacin Most cited articles on Garenoxacin Review articles on Garenoxacin Articles on Garenoxacin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Garenoxacin Images of Garenoxacin Photos of Garenoxacin Podcasts & MP3s on Garenoxacin Videos on Garenoxacin
Evidence Based Medicine
Cochrane Collaboration on Garenoxacin Bandolier on Garenoxacin TRIP on Garenoxacin
Clinical Trials
Ongoing Trials on Garenoxacin at Clinical Trials.gov Trial results on Garenoxacin Clinical Trials on Garenoxacin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Garenoxacin NICE Guidance on Garenoxacin NHS PRODIGY Guidance FDA on Garenoxacin CDC on Garenoxacin
Books
Books on Garenoxacin
News
Garenoxacin in the news Be alerted to news on Garenoxacin News trends on Garenoxacin
Commentary
Blogs on Garenoxacin
Definitions
Definitions of Garenoxacin
Patient Resources / Community
Patient resources on Garenoxacin Discussion groups on Garenoxacin Patient Handouts on Garenoxacin Directions to Hospitals Treating Garenoxacin Risk calculators and risk factors for Garenoxacin
Healthcare Provider Resources
Symptoms of Garenoxacin Causes & Risk Factors for Garenoxacin Diagnostic studies for Garenoxacin Treatment of Garenoxacin
Continuing Medical Education (CME)
CME Programs on Garenoxacin
International
Garenoxacin en Espanol Garenoxacin en Francais
Business
Garenoxacin in the Marketplace Patents on Garenoxacin
Experimental / Informatics
List of terms related to Garenoxacin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Garenoxacin (INN) is a quinolone antibiotic for the treatment of Gram-positive and Gram-negative bacterial infections.

Garenoxacin was discovered by Toyama Chemical Co., Ltd. of Tokyo, Japan, and is currently being marketed in Japan under the tradename Geninax. Schering-Plough holds worldwide rights for garenoxacin, except for Japan, South Korea, and China.

On February 13, 2006, Schering-Plough announced that the United States Food and Drug Administration has accepted the New Drug Application (NDA) for garenoxacin, and has been granted a 10-month review.

Schering-Plough later withdrew its application to the United States Food and Drug Administration, FDA, (August 20, 2006) for approval of the antibiotic Garenoxacin.

The European Medicines Agency (EMEA) had also been formally notified by Schering-Plough Europe (July 28 2007) of its decision to withdraw the application for a centralized marketing authorization for garenoxacin as well. Based on the CHMP review of the data regarding safety and efficacy (risk/benefit), the CHMP considered the application for garenoxacin to be unapprovable.